PMID- 36262511
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221021
IS  - 2364-3722 (Print)
IS  - 2196-9736 (Electronic)
IS  - 2196-9736 (Linking)
VI  - 10
IP  - 10
DP  - 2022 Oct
TI  - EUS-guided radiofrequency ablation of pancreatic/peripancreatic tumors and 
      oligometastatic disease: an observational prospective multicenter study.
PG  - E1380-E1385
LID - 10.1055/a-1922-4536 [doi]
AB  - Background and study aims  Endoscopic ultrasound-guided radiofrequency ablation 
      (EUS-RFA) is an emerging and minimally invasive technique that seems promising 
      for treatment of focal pancreatic and peripancreatic lesions. Our aim was to 
      prospectively evaluate the feasibility, safety, and technical and clinical 
      success of pancreatic and extra-pancreatic EUS-RFA. Patients and methods  We 
      prospectively collected clinical and technical data for all patients who 
      underwent EUS-RFA at two Belgian academic centers from June 2018 to February 
      2022. Feasibility, adverse events (AEs), and follow-up were also assessed. 
      Results  Twenty-nine patients were included, accounting for 35 lesions: 10 
      non-functioning neuroendocrine tumors (29 %), 13 pancreatic insulinomas (37 %), 
      one adenocarcinoma (3 %), and 11 intra-pancreatic and extra-pancreatic metastatic 
      lesions (31 %). Technical success was achieved in 100 % of cases, with a median 
      of three power applications per lesion (interquartile range 2). The majority of 
      patients (59 %) presented no collateral effects, three (10.3 %) developed 
      non-severe acute pancreatitis, and four (14 %) had mild abdominal pain. At 6 
      months follow-up (n = 25), 36 % of patients showed radiological complete 
      response, 16 % presented a significant partial response and 48 % showed < 50 % 
      decrease in diameter. At 12 months (n = 20), 30 % showed complete necrosis and 
      15 % > 50 % decrease in diameter. Hypoglycemia related to insulinoma was 
      immediately corrected in all 13 cases, with no recurrence during follow-up. 
      Conclusions  EUS-RFA is feasible, safe, and effective for treatment of pancreatic 
      and peripancreatic tumors. Larger and longer multicenter prospective studies are 
      warranted to establish its role in management of focal pancreatic lesions and 
      oligometastatic disease. Symptomatic insulinoma currently represent the best 
      indication.
CI  - The Author(s). This is an open access article published by Thieme under the terms 
      of the Creative Commons Attribution-NonDerivative-NonCommercial License, 
      permitting copying and reproduction so long as the original work is given 
      appropriate credit. Contents may not be used for commercial purposes, or adapted, 
      remixed, transformed or built upon. 
      (https://creativecommons.org/licenses/by-nc-nd/4.0/).
FAU - Figueiredo Ferreira, Mariana
AU  - Figueiredo Ferreira M
AD  - Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, 
      Erasme University Hospital, Universite Libre de Bruxelles, Belgium.
AD  - Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, 
      Saint-Pierre University Hospital, Universite Libre de Bruxelles, Belgium.
FAU - Garces-Duran, Rodrigo
AU  - Garces-Duran R
AD  - Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, 
      Cliniques Universitaires St. Luc, Universite Catholique de Louvain, Belgium.
FAU - Eisendrath, Pierre
AU  - Eisendrath P
AD  - Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, 
      Saint-Pierre University Hospital, Universite Libre de Bruxelles, Belgium.
FAU - Deviere, Jacques
AU  - Deviere J
AD  - Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, 
      Erasme University Hospital, Universite Libre de Bruxelles, Belgium.
FAU - Deprez, Pierre
AU  - Deprez P
AD  - Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, 
      Cliniques Universitaires St. Luc, Universite Catholique de Louvain, Belgium.
FAU - Monino, Laurent
AU  - Monino L
AD  - Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, 
      Cliniques Universitaires St. Luc, Universite Catholique de Louvain, Belgium.
FAU - Van Laethem, Jean-Luc
AU  - Van Laethem JL
AD  - Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, 
      Erasme University Hospital, Universite Libre de Bruxelles, Belgium.
FAU - Borbath, Ivan
AU  - Borbath I
AD  - Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, 
      Cliniques Universitaires St. Luc, Universite Catholique de Louvain, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20221017
PL  - Germany
TA  - Endosc Int Open
JT  - Endoscopy international open
JID - 101639919
PMC - PMC9576329
COIS- Competing interests The authors declare that they have no conflict of interest.
EDAT- 2022/10/21 06:00
MHDA- 2022/10/21 06:01
PMCR- 2022/10/01
CRDT- 2022/10/20 02:36
PHST- 2022/05/02 00:00 [received]
PHST- 2022/08/09 00:00 [accepted]
PHST- 2022/10/20 02:36 [entrez]
PHST- 2022/10/21 06:00 [pubmed]
PHST- 2022/10/21 06:01 [medline]
PHST- 2022/10/01 00:00 [pmc-release]
AID - 10.1055/a-1922-4536 [doi]
PST - epublish
SO  - Endosc Int Open. 2022 Oct 17;10(10):E1380-E1385. doi: 10.1055/a-1922-4536. 
      eCollection 2022 Oct.